IP Library Granted Patent US 7,393,666
Granted Patent B2
US 7,393,666 · App. 11/440,177 · Granted Jul 1, 2008

Use of hepatitis B X-interacting protein (HBXIP) in modulation of apoptosis

Assignee: Burnham Institute for Medical Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,393,666
App. No.
11/440,177
Granted
Jul 1, 2008
Kind
B2
Abstract

Novel methods of regulating cellular apoptosis by affecting the interaction of hepatitis B X-interacting protein (HBXIP) with Survivin are described. More specifically, these novel methods of enhancing apoptosis of neoplastic cells comprises inhibiting interaction of hepatitis B X-interacting protein (HBXIP) with Survivin.

Claims (16)

1. A method for identifying an effective agent that alters the association of Survivin and HBXIP comprising:

contacting Survivin and HBXIP in the presence or absence of a compound; and

detecting an altered association between Survivin and HBXIP, thereby determining whether said compound is an effective agent for altering association of Survivin with HBXIP.

2. The method of claim 1 , wherein Survivin and HBXIP associate in the presence of a compound and pro-Caspase-9.

3. The method of claim 1 , wherein the altered association between Survivin and HBXIP is detected by measuring the activation of pro-Caspase-9.

4. A method for identifying an effective agent that alters the association of Survivin and HBXIP comprising:

contacting Survivin and HBXIP under conditions that allow Survivin and HBXIP to associate in the presence of a compound, pro-Caspase-3, pro-Caspase-9, Apafl and cytochrome C; and

detecting an altered association between Survivin and HBXIP, thereby determining whether said compound is an effective agent for altering association of Survivin with HBXIP.

5. The method of claim 4 , wherein the altered association between Survivin and HBXIP is detected by measuring the activation of pro-Caspase-3.

6. The method of claim 5 , wherein the activation of pro-Caspase-3 is measured by monitoring the cleavage of caspase 3 substrate selected from the group consisting of DEVD-AFC, DEVD-pNA and DEVD-AMC.

7. A method for identifying an effective agent that alters the association of Survivin and HBXIP comprising:

contacting Survivin and HBXIP under conditions that allow Survivin and HBXIP to associate in the presence of a cell extract and a compound; and

detecting an altered association between Survivin and HBXIP, thereby determining whether said compound is an effective agent for altering association of Survivin with HBXIP.

8. The method of claim 7 , wherein said cell extract comprises pro-Caspase-9 and pro-Caspase-3.

9. The method of claim 7 , wherein the altered association between Survivin and HBXIP is detected by measuring the activation of pro-Caspase-3.

10. The method of claim 9 , wherein the activation of pro-Capase-3 is measured by monitoring the cleavage of a caspase 3 substrate selected from the group consisting of DEVD-AFC, DEVD-pNA and DEVD-AMC.

Assignments (4)
CONFIRMATORY LICENSE Recorded Aug 16, 2022
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 060813/0804 →
CHANGE OF NAME Recorded Nov 30, 2010
From: THE BURNHAM INSTITUTE
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 025414/0424 →
CHANGE OF NAME Recorded Nov 30, 2010
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 025464/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2006
From: TAMM, INGO; REED, JOHN C.
To: THE BURNHAM INSTITUTE
Reel/Frame 018582/0666 →
Continuity (3)
Division 1066597500 · Sep 18, 2003
Provisional Application 6041210900 · Sep 18, 2002
Related Publication 20060205008A1 · Sep 14, 2006